Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Triamcinolone Acetonide

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Liquid (Suspension) Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Triamcinolone Acetonide

Triamcinolone Acetonide

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Liquid (Suspension) Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Triamcinolone Acetonide

Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs. Treatment of inflammation and related disorders in horses. Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats. Species commonly shown: Both, Dog, Restricted During Pregnancy, Horse, Not For Meat Production.

Generic name
Triamcinolone Acetonide
Brand names
Triamcinolone Acetonide Suspension, Genesis® Topical Spray, Medalone Cream, Vetalog® Parenteral
Manufacturer
Multiple FDA labelers
Species
Both, Dog, Horse, Cat
Dosage forms
Liquid (Suspension), Liquid (Solution), Cream, Tablet
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Triamcinolone Acetonide Suspension Genesis® Topical Spray Medalone Cream Vetalog® Parenteral Vetalog Cream Triamcinolone Acetonide Vetalog Oral Powder Vetalog® VETAZINE Genesis
Dosage forms
Liquid (Suspension) Liquid (Solution) Cream Tablet Powder

Indications / Uses

Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs. Treatment of inflammation and related disorders in horses. Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.

Warnings / Contraindications

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Deafness, Loss of hearing, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Diarrhoea.

FAQ

Both, Dog, Restricted During Pregnancy, Horse, Not For Meat Production, Cat, Restricted During Pregnancy, Dog, Cat

Yes. Roxee shows this as prescription-only.

Liquid (Suspension), Liquid (Solution), Cream, Tablet

Related Conditions

Dystocia Metritis Pica Pruritus (itching, undifferentiated)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Do not use in viral infections
  • With bacterial infections appropriate antibacterial therapy should be used
  • Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy
  • Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
  • Do not use in horses intended for human consumption
  • Do not use in the treatment of laminitis
  • Intra-articular injection in equine leg injuries may produce osseous metaplasia
  • For mild inflammations, use once daily to once a week
  • For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs
  • Not intended for treatment of deep abscesses or deep-seated infections
  • Not for ophthalmic use
  • Elevated symmetrical dimethylarginine (1 reports)
  • Elevated blood urea nitrogen (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

Bloodwork changes are grouped in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Triamcinolone Acetonide; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-046437
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 29 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-046437
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-046437
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Elevated symmetrical dimethylarginine (1 reports), Elevated creatinine (1 reports), Elevated blood urea nitrogen (1 reports), Elevated amylase (1 reports), Eardrum rupture (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (1), Behavior (1), Other (26)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (22 reports), Dog (10 reports)

Breed metadata in reports Metadata only

Shar Pei (1), Domestic Shorthair (1), Domestic Longhair (1), Bulldog - French (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Triamcinolone Acetonide fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Do not use in viral infections, With bacterial infections appropriate antibacterial therapy should be used, Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emerge, Clinical and experimental data have demonstrated that corticosteroids administered orally or parente, Do not use in horses intended for human consumption

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Triamcinolone Acetonide brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-046437 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. SPL · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Do not use in viral infections
  • With bacterial infections appropriate antibacterial therapy should be used
  • Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy
  • Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis
  • Do not use in horses intended for human consumption

Most reported reactions:

  • Elevated symmetrical dimethylarginine (1 reports)
  • Elevated creatinine (1 reports)
  • Elevated blood urea nitrogen (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Cat, Dog, Horse
Indication / use
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Form / route / dose
Form: Cream, Liquid (Solution), Liquid (Suspension), Powder, Tablet
Route: Intra-Articular, Intralesional, Intramuscular, Intrasynovial, Oral, Subcutaneous, Topical
Confirm product label and patient-specific plan.
Warnings
  • High: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use …
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Cream, Liquid (Solution), Liquid (Suspension), Powder, Tablet
Identifiers:
ANADA: 200245 ANADA: 200275 ANADA: 200330 ANADA: 200459 NADA: 12198 NADA: 12258 NADA: 13624 NADA: 137694 NADA: 138869 NADA: 140810 NADA: 140847 NADA: 140879 NADA: 140889 NADA: 141003 NADA: 141210 NADA: 30045 NADA: 46146 NADA: 96676 NADA: 99388 NDC Package: 17033-122-15
Source metadata:

Warnings / Contraindications

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
4
Matching reports
4
Active filters
0
Reset
Drill into common report signals
Anaphylaxis (2) Elevated symmetrical dimethylarginine (SDMA) (2) Hypokalaemia (2) Abnormal histology NOS (1) Other (4) Digestive (3) Behavior (1) Effectiveness (1)
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-011925

Received 2026-03-13 · MSK · MSK

Non-serious
Species
Dog
Breed
Shar Pei
Size / weight
25-49 lb (14.97 Kilogram)
Age
4-7 years (5 Year)
Sex
Female Neutered
Region
USA
Reactions
TremblingSwollen jointFeverShaking
Body systems
Other
Outcomes
Recovered/Normal

USA-USFDACVM-2026-US-008733

Received 2026-02-25 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (6.622 Kilogram)
Age
8+ years (15 Year)
Sex
Female Unknown
Region
USA
Reactions
Death by euthanasiaOpen mouth breathingDehydrationEnophthalmos (see also Sunken eyes in Systemic disorders)HypersalivationWeak pulseCrackles on auscultationLateral recumbencyPale mucous membraneDepressionAnaphylaxisDecreased haematocritLeukocytosis NOSMonocytosisBasophiliaThrombocytosisHyperglycaemiaElevated creatinineElevated symmetrical dimethylarginine (SDMA)HypocalcaemiaHypokalaemiaProlonged bleeding NOSAbnormal radiograph finding
Body systems
OtherDigestiveNeurologic
Outcomes
Euthanized

USA-USFDACVM-2026-US-001377

Received 2026-01-12 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Longhair
Size / weight
Under 10 lb (4.064 Kilogram)
Age
8+ years (15 Year)
Sex
Female Unknown
Region
USA
Reactions
DermatitisSkin ulcerLack of efficacy - NOSAbnormal histology NOSBehavioural disorder NOSVocalisationTachycardiaHigh blood pressureRetinal disorder NOSGranulomaDecreased appetitePain NOSWeight lossAbnormal menace reflex testDilated pupilsLoss of visionSkin irritationInjection site dermatitisElevated blood urea nitrogen (BUN)PacingElevated amylaseHypokalaemiaElevated symmetrical dimethylarginine (SDMA)Vomiting bile
Body systems
OtherEffectivenessBehaviorDigestive
Outcomes
Ongoing

USA-USFDACVM-2025-US-071520

Received 2025-12-01 · MSK · MSK

Serious
Species
Dog
Breed
Bulldog - French
Size / weight
10-24 lb (10.795 Kilogram)
Age
1-3 years (3 Year)
Sex
Female Unknown
Region
USA
Reactions
VomitingBreathing difficultyCyanosisUrinary incontinenceAnaphylaxis
Body systems
DigestiveOther
Outcomes
Recovered/Normal

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
29
Species represented
2
Grouped by Body System
Digestive (4) · Drooling, Diarrhea, Decreased appetite Neurologic (1) · Depression Behavior (1) · Behavioral disorder (unspecified) Other (26) · Elevated symmetrical dimethylarginine, Elevated creatinine, Elevated blood urea nitrogen
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Digestive 1 Dog 1
Other 1 Cat 1

Species coverage: Cat (22) Dog (10)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Neurologic Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Behavior Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Medalone Cream SPL · SPL Triamcinolone Acetonide SPL · SPL Vetalog Cream SPL · SPL

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

11

FOI

8

Medalone Cream

SPL · SPL

Open original
FDA Structured Product Label

Medalone Cream

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Med-Pharmex, Inc.
ANADA
200-275
Status
RX
Form
Cream
Route
Topical
Species
Dog
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.

Dogs

Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

Triamcinolone Acetonide

SPL · SPL

Open original
FDA Structured Product Label

Triamcinolone Acetonide

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA Inc.
NADA
13624
Status
RX
Form
Tablet
Route
Oral
Species
Dog • Cat
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.

Dogs

Indication
The drug is indicated for use in dogs for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication
The drug is indicated for use in cats for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Vetalog Cream

SPL · SPL

Open original
FDA Structured Product Label

Vetalog Cream

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA Inc.
NADA
46146
Status
RX
Form
Cream
Route
Topical
Species
Dog
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.

Dogs

Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

Vetalog Oral Powder

SPL · SPL

Open original
FDA Structured Product Label

Vetalog Oral Powder

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA Inc.
NADA
99388
Status
RX
Form
Powder
Route
Oral
Species
Horse
Composition / specifications
Each 15 grams of triamcinolone acetonide oral powder contains 10 milligrams of triamcinolone acetonide.

Horses

Indication
The drug is used as an anti-inflammatory agent.
Dosage
It is administered at a dosage of 0.005 to 0.01 milligram triamcinolone acetonide per pound of body weight twice daily, sprinkled (top-dressed) on a small portion of feed. Treatment may be initiated with a single dose of sterile triamcinolone acetonide suspension USP followed after 3 or 4 days with the use of triamcinolone acetonide oral powder.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.

Triamcinolone Acetonide Suspension

SPL · SPL

Open original
FDA Structured Product Label

Triamcinolone Acetonide Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
NADA
138-869
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular, Intra-Articular, Intrasynovial, Subcutaneous, Intralesional
Species
Dog • Horse • Cat
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.

Horses

Indication
Treatment of inflammation and related disorders.
Dosage
Single injection of 0.01 to 0.02 milligrams intramuscularly or subcutaneously per pound of body weight. Usual dose, 12 to 20 milligrams intramuscularly or subcutaneously. Or administer single injection of 6 to 18 milligrams intra-articularly and intrasynovially dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Not for use in horses intended for food. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Vetalog® Parenteral

SPL · SPL

Open original
FDA Structured Product Label

Vetalog® Parenteral

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
12198
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular, Intralesional, Intra-Articular, Subcutaneous, Intrasynovial
Species
Dog • Cat
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.

Dogs

Indication
Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication
Treatment of inflammation and related disorders in horses.
Dosage
Intramuscular or subcutaneous: Single injection of 0.01 to 0.02 milligrams per pound of body weight. Usual dose, 12 to 20 milligrams. Intra-articular and intrasynovial: Single injection of 6 to 18 milligram dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams.
Limitations

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental da

Indication
Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Vetalog®

SPL · SPL

Open original
FDA Structured Product Label

Vetalog®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
137-694
Status
RX
Form
Tablet
Route
Oral
Species
Dog • Cat
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.

Cats

Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

VETAZINE

SPL · SPL

Open original
FDA Structured Product Label

VETAZINE

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Modern Veterinary Therapeutics, LLC
ANADA
200-459
Form
Cream
Route
Topical
Species
Dog
Composition / specifications
1 mg of triamcinolone acetonide per gram

Dogs

Indication
For topical treatment of allergic dermatitis and summer eczema in dogs.
Dosage
Apply by rubbing into the affected areas two to four times daily for 4 to 10 days.

Genesis® Topical Spray

SPL · SPL

Open original
FDA Structured Product Label

Genesis® Topical Spray

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Virbac AH, Inc.
NADA
141-210
Status
RX
Form
Liquid (Solution)
Route
Topical
Species
Dog
Composition / specifications
Each milliliter of solution contains 0.15 milligrams (0.015%) triamcinolone acetonide.

Dogs

Indication
For the control of pruritus associated with allergic dermatitis.
Dosage
Apply sufficient pump sprays to uniformly and thoroughly wet the affected areas while avoiding run off of excess product. Administer twice daily for 7 days, then once daily for 7 days, then every other day for an additional 14 days (28 days total).
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For topical use in dogs only.

Genesis SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Genesis. Use the source link for the full official labeling record.

Triamcinolone acetonide SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Triamcinolone acetonide. Use the source link for the full official labeling record.

ucm061703.pdf

FOI · FOI

Open original

N138869_Org_1_6_1987..pdf

FOI · FOI

Open original

ucm117775.pdf

FOI · FOI

Open original

N140810_Org_5_31_1988.pdf

FOI · FOI summary

Open original

ucm061671.pdf

FOI · FOI summary

Open original

ucm061795.pdf

FOI · FOI summary

Open original

N140879_Org_8_2_1989.pdf

FOI · FOI summary

Open original

N140847_Org_9_30_1988.pdf

FOI · FOI summary

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Genesis Triamcinolone acetonide
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog, Horse
Rx/OTC: RX
Form/route: Cream, Liquid (Solution), Liquid (Suspension), Powder, Tablet • Intra-Articular, Intralesional, Intramuscular, Intrasynovial, Oral, Subcutaneous, Topical
Applications: ANADA 200-275 • NADA 13624 • NADA 46146 • NADA 99388 • NADA 138-869 • NADA 12198 • NADA 137-694 • ANADA 200-459 • NADA 141-210
NDC: Packages 51311-105-08 51311-105-16 73309-105-01 • Products 51311 73309
Documents: 3 (FOI: 3) • SPL: 9 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 9 • Cat 45 • View
Case summaries: 4 (showing 4) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Elevated symmetrical dimethylarginine (1) Elevated creatinine (1) Elevated blood urea nitrogen (1) Elevated amylase (1) Eardrum rupture (1) Ear discharge (1) Drooling (1) Dilated pupils (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200245 ANADA: 200275 ANADA: 200330 ANADA: 200459 NADA: 12198 NADA: 12258 NADA: 13624 NADA: 137694 NADA: 138869 NADA: 140810 NADA: 140847 NADA: 140879 NADA: 140889 NADA: 141003 NADA: 141210 NADA: 30045 NADA: 46146 NADA: 96676 NADA: 99388 NDC Package: 17033-122-15 NDC Package: 17033-122-30 NDC Package: 17033-122-75 NDC Package: 51311-105-08 NDC Package: 51311-105-16
Package NDC Product NDC Form / Route Status
17033-122-15 17033 -
17033-122-30 17033 -
17033-122-75 17033 -
51311-105-08 51311 -
51311-105-16 51311 -
73309-105-01 73309 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Genesis SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Triamcinolone acetonide SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • N140810_Org_5_31_1988.pdf • FOI summary • Official • Jan. 21, 2025
    FDA FOI summary for application 140810
  • ucm061703.pdf • FOI summary • Official • Dec. 26, 2023
    FDA FOI summary for application 200275
  • ucm061671.pdf • FOI summary • Official • Dec. 26, 2023
    FDA FOI summary for application 200245
  • N138869_Org_1_6_1987..pdf • FOI summary • Official • Feb. 1, 2018
    FDA FOI summary for application 138869
  • ucm061795.pdf • FOI summary • Official • Dec. 27, 2017
    FDA FOI summary for application 200330
  • N140879_Org_8_2_1989.pdf • FOI summary • Official • May 17, 2017
    FDA FOI summary for application 140879
  • N140847_Org_9_30_1988.pdf • FOI summary • Official • May 17, 2017
    FDA FOI summary for application 140847
  • ucm117775.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141210

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 129 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Deafness, Loss of hearing, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficac… (Clinical, 2026-04-11)
  • contraindications: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic ne… (Official, 2026-04-12)
  • contraindications: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic ne… (Official, 2026-04-11)
  • contraindications: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic ne… (Official, 2026-02-12)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-08-06)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-08-05)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-08-04)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-08-03)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-08-02)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-08-01)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-31)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-30)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-29)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-28)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-27)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-26)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-25)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-25)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-22)
  • indications: For the control of pruritus associated with allegic dermatitis in dogs. Medalone Cream (Triamcinolone Acetonide Cream) is indicated for topical treatment of al… (Official, 2026-07-22)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Medalone Cream
RX
Triamcinolone Acetonide
Cream • Topical
Label highlights
Official documents
Med-Pharmex, Inc. ANADA 200-275 W Dec 26, 2023
Triamcinolone Acetonide
RX
Triamcinolone Acetonide
Tablet • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA Inc. NADA 13624 W May 3, 2023
Vetalog Cream
RX
Triamcinolone Acetonide
Cream • Topical
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA Inc. NADA 46146 W May 3, 2023
Vetalog Oral Powder
RX
Triamcinolone Acetonide
Powder • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA Inc. NADA 99388 W May 3, 2023
Triamcinolone Acetonide Suspension
RX
Triamcinolone Acetonide
Liquid (Suspension) • Intramuscular, Intra-Articular, Intrasynovial, Subcutaneous, Intralesional
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. NADA 138-869 Approved Feb 1, 2018
Vetalog® Parenteral
RX
Triamcinolone Acetonide
Liquid (Suspension) • Intramuscular, Intralesional, Intra-Articular, Subcutaneous, Intrasynovial
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 12198 Approved Jan 9, 2018
Vetalog®
RX
Triamcinolone Acetonide
Tablet • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 137-694 Approved Feb 23, 2017
VETAZINE
Triamcinolone Acetonide
Cream • Topical
Label highlights
Official documents
Modern Veterinary Therapeutics, LLC ANADA 200-459 W Aug 16, 2016
Genesis® Topical Spray
RX
Triamcinolone Acetonide
Liquid (Solution) • Topical
Label highlights
Official documents
Virbac AH, Inc. NADA 141-210 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.
Dogs
Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.
Dogs
Indication
The drug is indicated for use in dogs for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
The drug is indicated for use in cats for its anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day. Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear.
Limitations
The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
Triamcinolone acetonide cream contains 0.1 percent triamcinolone acetonide in an aqueous vanishing cream base.
Dogs
Indication
The drug is recommended for use on dogs as an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.
Dosage
The drug is applied by rubbing into affected areas two to four times daily for 4 to 10 days.
Limitations
For use only by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Horse
Composition / specifications
Each 15 grams of triamcinolone acetonide oral powder contains 10 milligrams of triamcinolone acetonide.
Horses
Indication
The drug is used as an anti-inflammatory agent.
Dosage
It is administered at a dosage of 0.005 to 0.01 milligram triamcinolone acetonide per pound of body weight twice daily, sprinkled (top-dressed) on a small portion of feed. Treatment may be initiated with a single dose of sterile triamcinolone acetonide suspension USP followed after 3 or 4 days with the use of triamcinolone acetonide oral powder.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.
Horses
Indication
Treatment of inflammation and related disorders.
Dosage
Single injection of 0.01 to 0.02 milligrams intramuscularly or subcutaneously per pound of body weight. Usual dose, 12 to 20 milligrams intramuscularly or subcutaneously. Or administer single injection of 6 to 18 milligrams intra-articularly and intrasynovially dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Not for use in horses intended for food. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dogs
Indication
Treatment of inflammation and related disorders and management and treatment of acute arthritis and allergic and dermatologic disorders.
Dosage
Single injection of 0.05 to 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligrams intramuscularly or subcutaneously per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Or administer 1.2 to 1.8 milligrams intralesionally, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams intralesionally and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams intralesionally. Or administer a single injection of 1 to 3 milligrams intra-articularly and intrasynovially, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams intra-articularly and intrasynovially.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat
Composition / specifications
Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide.
Dogs
Indication
Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Horses
Indication
Treatment of inflammation and related disorders in horses.
Dosage
Intramuscular or subcutaneous: Single injection of 0.01 to 0.02 milligrams per pound of body weight. Usual dose, 12 to 20 milligrams. Intra-articular and intrasynovial: Single injection of 6 to 18 milligram dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams.
Limitations

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental da
Indication
Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.
Dosage
Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams.
Limitations
Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat
Composition / specifications
Each tablet contains 0.5 and 1.5 milligrams of the drug.
Cats
Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dogs
Indication
The drug is indicated for anti-inflammatory activity.
Dosage
An initial daily dosage of 0.05 milligram per pound of body weight is usually sufficient to control symptoms, although up to 0.1 milligram per pound of body weight may be given daily if response to the smaller dose is inadequate. As soon as feasible, and in any case within 2 weeks, dosage should be reduced gradually to maintenance levels of 0.0125 to 0.025 milligram per pound of body weight per day.
Limitations
Therapy should be discontinued by a gradual reduction in dosage after the condition has been controlled for several days. Therapy may be initiated with a single dose of sterile triamcinolone acetonide suspension veterinary in which case the tablet dosage should be administered beginning 5 to 7 days after the injection or when symptoms reappear. The labeling shall comply with the requirements of 510.410 of this chapter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
1 mg of triamcinolone acetonide per gram
Dogs
Indication
For topical treatment of allergic dermatitis and summer eczema in dogs.
Dosage
Apply by rubbing into the affected areas two to four times daily for 4 to 10 days.
Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
Each milliliter of solution contains 0.15 milligrams (0.015%) triamcinolone acetonide.
Dogs
Indication
For the control of pruritus associated with allergic dermatitis.
Dosage
Apply sufficient pump sprays to uniformly and thoroughly wet the affected areas while avoiding run off of excess product. Administer twice daily for 7 days, then once daily for 7 days, then every other day for an additional 14 days (28 days total).
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For topical use in dogs only.

FDA page: Open in Animal Drugs @ FDA

Usage

Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs. Treatment of inflammation and related disorders in horses. Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For mild inflammations, use once daily to once a week. For severe conditions, apply initially two to three times daily, decreasing frequency as improvement occurs. Not intended for treatment of deep abscesses or deep-seated infections. Not for ophthalmic use. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Drooling (1) • Dog Diarrhea (1) • Cat Decreased appetite (1) • Cat Appetite loss (1) • Dog

Showing top 5 for Digestive.

Neurologic
Depression (1) • Cat

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other
Elevated symmetrical dimethylarginine (1) • Cat Elevated creatinine (1) • Cat Elevated blood urea nitrogen (1) • Cat Elevated amylase (1) • Cat Eardrum rupture (1) • Cat
Show more (21)
Ear infection NOS (1) • Dog Ear discharge (1) • Cat Dry skin (1) • Dog Dilated pupils (1) • Cat Dermatitis (1) • Cat Dehydration (1) • Cat Decreased haematocrit (1) • Cat Death by euthanasia (1) • Cat Deafness (1) • Dog Cyanosis (1) • Dog Crackles on auscultation (1) • Cat Breathing difficulty (1) • Dog Blindness (1) • Cat Basophilia (1) • Cat Application site scratching (1) • Dog Anaphylaxis (1) • Dog Accidental exposure (1) • Dog Abnormal radiograph finding (1) • Cat Abnormal menace reflex test (1) • Cat Abnormal histology NOS (1) • Cat Abnormal breathing (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shar Pei, Female, 5 year, 14.97 kilogram • Drug: MSK, Topical • Reactions: Trembling, Swollen joint, Fever, Shaking • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-011925
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 5.00 Year
  • Weight: 14.970 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Topical
Reactions Reported:
Trembling Swollen joint Fever Shaking
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 15 year, 6.622 kilogram • Drug: MSK, Unassigned, Subcutaneous • Reactions: Death by euthanasia, Open mouth breathing, Dehydration, Enophthalmos, Drooling… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2026-US-008733
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 15.00 Year
  • Weight: 6.622 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Unassigned
Reactions Reported:
Death by euthanasia Open mouth breathing Dehydration Enophthalmos Drooling Weak pulse Crackles on auscultation Lateral recumbency Pale mucous membrane Depression Anaphylaxis Decreased haematocrit Leukocytosis NOS Monocytosis Basophilia Thrombocytosis Hyperglycaemia Elevated creatinine Elevated symmetrical dimethylarginine Hypocalcaemia Hypokalaemia Prolonged bleeding NOS Abnormal radiograph finding
Outcomes: Euthanized

Cat, Domestic Longhair, Female, 15 year, 4.064 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Dermatitis, Skin ulcer, Lack of efficacy - NOS, Abnormal histology NOS, Behavioral disorder (unspecified)… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-001377
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 15.00 Year
  • Weight: 4.064 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Dermatitis Skin ulcer Lack of efficacy - NOS Abnormal histology NOS Behavioral disorder (unspecified) Vocalisation Tachycardia High blood pressure Retinal disorder NOS Granuloma Decreased appetite Pain NOS Weight loss Abnormal menace reflex test Dilated pupils Loss of vision Skin irritation Injection site dermatitis Elevated blood urea nitrogen Pacing Elevated amylase Hypokalaemia Elevated symmetrical dimethylarginine Vomiting bile
Outcomes: Ongoing

Dog, Bulldog - French, Female, 3 year, 10.795 kilogram • Drug: MSK, Parenteral • Reactions: Vomiting, Breathing difficulty, Cyanosis, Urinary incontinence, Anaphylaxis • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-071520
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 10.795 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Parenteral
Reactions Reported:
Vomiting Breathing difficulty Cyanosis Urinary incontinence Anaphylaxis
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.